Literature DB >> 11919134

Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes.

Louis Monnier1, Claude Colette, Rémy Rabasa-Lhoret, Hélène Lapinski, Cécile Caubel, Antoine Avignon, Hélène Boniface.   

Abstract

OBJECTIVE: To determine whether, over daytime, one or several hyperglycemic excursions exist that can be general failures in the glycemic control of patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In 200 non-insulin-using patients with type 2 diabetes, diurnal plasma glucose and insulin profiles were studied. Plasma glucose concentrations were measured after an overnight fast (at 8:00 A.M. immediately before breakfast), during the postprandial period (at 11:00 A.M. and 2:00 P.M.), and during the postabsorptive period (at 5:00 P.M., extended postlunch time).
RESULTS: In the population considered as a whole, prelunch glucose concentrations (12.0 mmol/l) were found to be significantly increased (P < 0.0001) when compared with those observed at 8:00 A.M. (8.8 mmol/l), at 2:00 P.M. (10.5 mmol/l), and at 5:00 P.M. (8.6 mmol/l). Similar significant excursions (P < 0.0001) in prelunch glucose were observed within subsets of patients selected from the following criteria: 1) body weight, 2) HbA(1c), 3) categories of treatment, and 4) residual beta-cell function. From the calculation of areas under the daytime glucose curves, the relative contributions of postprandial and fasting glucose to the total glucose increment were found to be similar.
CONCLUSIONS: High plasma glucose excursions over morning periods seem to be a permanent failure in non-insulin-using patients with type 2 diabetes, whatever the clinical (BMI), biological (HbA(1c)), therapeutic, and pathophysiological (residual beta-cell function) status. Midmorning glucose testing should be recommended for detecting such abnormalities and for correcting them with appropriate therapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11919134     DOI: 10.2337/diacare.25.4.737

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  22 in total

1.  Exercise at lunchtime: effect on glycemic control and oxidative stress in middle-aged men with type 2 diabetes.

Authors:  Jonida Haxhi; Gaetano Leto; Alessandro Scotto di Palumbo; Paola Sbriccoli; Laura Guidetti; Cristina Fantini; Raffaella Buzzetti; Daniela Caporossi; Luigi Di Luigi; Massimo Sacchetti
Journal:  Eur J Appl Physiol       Date:  2015-12-28       Impact factor: 3.078

2.  A case of an elderly patient with insulin-dependent diabetes and dementia receiving one basal insulin plus one bolus insulin injections a day for 6 months.

Authors:  Taichi Minami; Jun Shirakawa; Akiko Kameda; Yoichi Suzuki; Kaoru Watanabe; Taku Yamada; Hiroko Hiiragi; Soichiro Takeda; Mayuko Takahashi; Yasuo Terauchi
Journal:  Diabetol Int       Date:  2020-07-02

3.  Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus.

Authors:  E Bonora; G Corrao; V Bagnardi; A Ceriello; M Comaschi; P Montanari; J B Meigs
Journal:  Diabetologia       Date:  2006-03-11       Impact factor: 10.122

4.  Comparison of multiple and novel measures of dietary glycemic carbohydrate with insulin resistant status in older women.

Authors:  Therese A O'Sullivan; Alexandra P Bremner; Sheila O'Neill; Philippa Lyons-Wall
Journal:  Nutr Metab (Lond)       Date:  2010-04-07       Impact factor: 4.169

5.  Relation of fasting and postprandial and plasma glucose with hemoglobinA1c in diabetics.

Authors:  Shahram Haddadinezhad; Nargess Ghazaleh
Journal:  Int J Diabetes Dev Ctries       Date:  2010-01

6.  Targeting prandial hyperglycemia: how important is it and how best to do this?

Authors:  Louis Monnier; Claude Colette
Journal:  Curr Diab Rep       Date:  2008-10       Impact factor: 4.810

7.  Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks.

Authors:  J F Ortega; F Morales-Palomo; M Ramirez-Jimenez; A Moreno-Cabañas; R Mora-Rodríguez
Journal:  Acta Diabetol       Date:  2020-02-04       Impact factor: 4.280

8.  Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).

Authors:  Vivian A Fonseca; Ricardo Alvarado-Ruiz; Denis Raccah; Gabor Boka; Patrick Miossec; John E Gerich
Journal:  Diabetes Care       Date:  2012-03-19       Impact factor: 19.112

Review 9.  Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.

Authors:  Catherine A Schnabel; Matthew Wintle; Orville Kolterman
Journal:  Vasc Health Risk Manag       Date:  2006

Review 10.  Target for glycemic control: concentrating on glucose.

Authors:  Louis Monnier; Claude Colette
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.